No abstract

No abstract

Introduction: Among a large number of immunomodulation agents, a special role belongs to herbal medicines. They differ in relative harmlessness and high efficiency, both with system and local use. Clinical and immunological efficacy of Esberitox phytopreparation (Schaper&Brummer, Germany) in a number of diseases of viral and microbial origin has been shown. This report presents data on the effect of Esberitox on the factors of local immunity of the oral cavity in patients with chronic pharyngitis, tonsillitis and periodontitis with systemic use of Esberitox in monotherapy. Methods: The oropharyngeal secret of 10 patients with chronic tonsillitis (CT), 11 patients with chronic pharyngitis (CP), (all patients after tonsillectomy), 10 patients with chronic periodontitis was investigated. Patients were given monotherapy with «Esberitox» for 10 days (CP), according to the manufacturer's instructions for use of the drug. In addition, 9 practically healthy persons (K) of the same age (18-50 years) were examined. The ELISA method was used to determine the class A immunoglobulins (secretory and monomeric), IgG, α-interferon, interleukin-1β, levels of immune complexes. Statistics: Mann-Whitney U-test. Results: Studies have shown that in patients with chronic inflammatory diseases of the oral cavity there is a decrease in the protective factors of local immunity – the level of secretory IgA, antiviral factor – α-interferon and an increase in the level of pro-inflammatory cytokine – interleukin-1β, monomeric form of IgA and the number of immune complexes. The use of «Esberitox» as a monotherapy was accompanied by an increase in the concentration of class A secretory immunoglobulin, the «normalization» of the α-interferon content (increase in concentration) and interleukin-1β (decrease in content). Conclusion: The resulting positive effects from the use of esberitox allow us to recommend the drug as part of the complex therapy of chronic diseases of the oropharynx, and in the form of monotherapy.